Efficacy and safety/tolerability of ragweed MATA MPL, a randomized, placebo-controlled, double-blind study.

Trial Profile

Efficacy and safety/tolerability of ragweed MATA MPL, a randomized, placebo-controlled, double-blind study.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2012

At a glance

  • Drugs Ragweed allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis; Ragweed pollen hypersensitivity; Seasonal allergic rhinitis
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Most Recent Events

    • 21 Dec 2009 Results were presented at the 2009 Annual Meeting of the American College of Allergy, Asthma and Immunology.
    • 23 Jun 2009 Actual patient number (993) added as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top